The authors describe key challenges facing the clinical trials community and propose solutions to these issues, including the role the Clinical Trials Transformation Initiative can play in addressing these issues. Specifically, the authors reflect on clinical trial globalization and the harmonization of frameworks and requirements across regions; the challenges associated with balancing the desire for external validity, pragmatic trials, and precision medicine; clinical trial transparency; and operational complexity and the expense of clinical trials. By addressing these challenges, future clinical trials will be more feasible, relevant, and credible, and support both the continuing altruistic contributions of patients and the collection of more meaningful data.
Introduction
In 1948, the iconic trial of streptomycin for pulmonary tuberculosis, 1 the first modern randomized controlled trial, marked the dawn of a new era in clinical research. Clinical trials have since undergone an astounding evolution in terms of their scientific and statistical underpinnings and impact on regulation. The Clinical Trials Transformation Initiative (CTTI) has played an important role in supporting this development over the past decade, by addressing and proposing solutions for a broad range of operational and scientific trial-related issues.
The evolution of clinical trials has not reached its end, and debate surrounding the need for novel adaptive trial designs, platform trials, and other forms of novel trial design continues. 2, 3 Furthermore, novel trial endpoints generated by mobile technology 4 and drugbiomarker co-development present additional organizational challenges across disease states. Here, the authors reflect on several key challenges facing the broader clinical trial community and propose solutions to these challenges that will lead to more feasible, relevant, and credible future clinical trials that support both the continuing altruistic contributions of patients and the collection of more meaningful data. Within this supplement, the authors focus primarily on clinical trials intended to support marketing authorizations for pharmaceutical products. Each key challenge is described below.
Clinical trial globalization
For most of the 20th century, clinical trials were carried out in a disjointed and compartmentalized fashion around the world. With the success of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 5 this approach has changed and evolved for the better. Today, the goal of many clinical trials is to support marketing authorization of new drugs globally. By necessity, many clinical trials became global trials.
While global trials may have increased the efficiency of clinical drug development, they present three particular challenges: (1) some participating regions seek the inclusion of predefined numbers of patients from their territory and health-care environment; (2) regulators in each region often have divergent requirements for endpoints in various therapeutic areas (e.g. antimicrobials, liver diseases, and histology-based endpoints), durations (e.g. type II diabetes in pediatrics), comparators (e.g. hypertension, active versus placebo-control), and other trial characteristics, making development of a single, globally acceptable trial protocol difficult; and (3) while much has indeed been harmonized, the detailed regulatory frameworks or ethical requirements governing the approval and conduct of clinical trials at the national level increase the operational complexity of running a trial across several regions.
To best address the challenges posed by globalization, a multipronged approach is required. First, in order to harmonize evidentiary standards, regulators must be willing to work together to synchronize requirements on a protocol-by-protocol basis. 6 To date, ICH has not been able to drive globally harmonized, therapeutic area-specific guidelines or standard protocols. In addition, for each clinical trial, regulatory procedural requirements should be aligned to enable concurrent trial initiation across regions and implement common procedures to reduce operational complexity. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have recognized the importance of trying to achieve alignment and have established both formal and informal platforms to discuss therapeutic-and product-specific developments, such as clusters in the major therapeutic areas and voluntary EMA-FDA parallel Scientific Advice and Qualification of Novel Methodologies. For example, broad agreement between the FDA and the EMA recently encouraged an innovative approach to development of medicines for Gaucher's disease through agreement on evidence standards, including extrapolation of available clinical data for predicting drug behavior in children and adolescents and encouraging a multi-arm, multi-company approach to reduce the number of children needed in clinical trials. 7 The EMA, the Japanese Pharmaceuticals and Medical Devices Agency, and FDA have also agreed to align their data requirements for clinical development of new antibiotics, including those for infections caused by multidrug-resistant organisms. 8 Finally, recent collaboration between the FDA, EMA, and Health Canada in the area of pediatric pulmonary arterial hypertension 9 represent yet another way in which more efficient and meaningful clinical trials can be conducted. This dedication to efficiency and more meaningful data collection by regulatory agencies maximizes the contributions of both patients and study sponsors, highlighting the need for continuing efforts in this vein.
Second, in addition to collaborative efforts surrounding protocol and regulatory standards, the development of innovative methodology is critical to enable preplanned extrapolation of clinical trial results, especially for populations not otherwise sufficiently represented, to reach statistical power. These methods must strike a balance between maintaining clinical trial efficiency, that is, keeping sample sizes within manageable limits and at the same time satisfying regional regulatory requirements. Novel techniques may involve extrapolations based on reuse of existing data to better understand trial populations or ''borrowing'' patient-level data from past or concurrent clinical trials (e.g. pooling placebo or standard treatment arm data). 10, 11 To make the most of both existing and emerging methods, sponsors must engage in proactive analyses to anticipate regional differences conferred by intrinsic and extrinsic factors. 12 Patient populations: external validity and precision medicine
To best make improvements in clinical trial efficiency, it is critical to recognize two intertwined conundrums challenging clinical trial organization: first, the tradeoff between external validity and trial efficiency and avoidance of false-negatives, and second, the advantage of including stratified subpopulations must be balanced against those of obtaining data for the broad population.
External validity
A primary criticism of randomized controlled trials is that they represent a highly artificial setting in which measured efficacy of a treatment in a tightly controlled group of patients cannot be directly translated to treatment effectiveness in ''real-world'' patient populations. Patient groups involved in randomized controlled trials are often selected to avoid confounding variables. For this reason, randomized controlled trials have low external validity and do not adequately represent the patient populations seen by clinicians in everyday practice. The gap between efficacy in clinical trials and effectiveness in daily practice may be due to a number of reasons, including poor patient adherence and persistence, inappropriate prescribing, co-medication, and greater variability in patient characteristics. In some instances, the gap has led to a negative benefit-risk assessment and, consequently, the need to take drugs off the market even though they had a favorable benefitrisk assessment at the time of licensing (examples include cerivastatin, mibefradil, and rimonabant 13 ). Although the intuitive solution to this issue is to accept a broader, more realistic patient population into clinical trials by relaxing inclusion and exclusion criteria, this can have the undesired effect of increasing variability and decreasing the signal-to-noise ratio. Increased variability and noise escalate the required trial sample size, posing a direct challenge to the goal of improving efficiency. In the worst case, a broader patient population may lead to false-negative trials, denying important patient subgroups potentially valuable treatments. 13 Although pragmatic clinical trials, 14 which take place in community-based health-care settings, address this conundrum somewhat, they are not a universal solution; even pragmatic clinical trials cannot escape this basic trade-off.
The way to address this issue is not by making clinical trials ''noisier'' but by acknowledging the gap between efficacy and effectiveness and planning clinical trials so that they may realistically address this gap as a central part of the overall drug development program. Potential strategies include a prospective efficacy-toeffectiveness approach, pairing clinical trials information with complementary real-world data gathered after market launch. 15 
Precision medicine and subgroup analysis
Compounding the signal-to-noise issue associated with the call for wider selection criteria in clinical trials are current efforts to gather data in support of tailoring treatment to specific patient types, a practice also known as precision medicine. If the promise of precision medicine is to be realized, clinical trial populations must be defined on an even more granular level, resulting in the need to stratify clinical trials into more and smaller subgroups of treatment-eligible patients. In some instances, a single large trial with preplanned subgroup analyses is sufficient to understand differential treatment effects. However, as our understanding of the complexities underlying patient heterogeneity continues to grow, even the largest of trials will fail to accommodate all known subpopulations. This issue is further compounded in clinical trials that evaluate stratified combination treatments.
The current model of large clinical trials with multiple subgroup analyses is clearly not sustainable. The need to understand benefits and harms across patient subpopulations inherent to precision medicine requires more and smaller clinical trials. Innovative trial designs such as basket designs, integration of randomized controlled trials and real-world data, development of more predictive preclinical/animal models (e.g. cystic fibrosis for which around 2000 mutations are known) or, most likely, a combination of the above need to be used.
To address both issues of external validity and the continuing expansion of patient subgroups, large clinical trials with inconsistently defined subpopulations and highly restricted (and frequently unfeasible) selection criteria must be replaced by more numerous, smaller clinical trials. Multiple smaller trials can enable the study of efficacy in subgroups with different disease and host factors, as well as different doses (dose ranges), or combinations and treatment sequences. Many subgroups will probably not have the same dose-exposure-response relationship and the search for the one ''optimal'' dose or regimen may be naı¨ve. 16 Ideally, these smaller clinical trials will share both common data standards and utilize a subset of selection criteria and endpoints that may be taken from a common pool. This arrangement will permit clinical trials to be tailored to a specific population or question while facilitating the collection of small and focused datasets.
''Meta-clinical trials'' powered to answer more general questions relevant to a larger, more general population can then combine these small focused datasets. The findings from collections of smaller clinical trials may be further complemented by real-world evidence.
As the environment of clinical trials continues to evolve, methodology development must rise to meet the challenges of integrating randomized clinical trial data and real-world data by developing novel trial designs (and analyses) and extrapolating across patient subgroups. This development is critical for enabling robust conclusions about the benefits and harms of treatments in different settings and populations. To achieve the level of collaboration required to meet these challenges, a joint effort between regulators, industry, and academic methodologists is critical. 17, 18 Involvement of organizations such as the CTTI 19 and ICH 6 is central to guiding these processes by facilitating research and the development of guidelines and tools to support the design of more informative and efficient clinical trials. 19 
Operational complexity and the expense of clinical trials
The operational complexity and expense of running a clinical trial has increased dramatically over the past decades and continues to do so. This increase is driven primarily by an ever-growing ''superstructure'' that includes more intensive and complex monitoring, reporting rules, and governance. While some of the growing complexity of clinical trials can be traced to ICH guidelines and regulatory requirements, many investigators and even regulators would argue that there is also over-interpretation and over-implementation of these by many actors in the clinical trials ecosystem. 20, 21 Overall, this increase in complexity and cost reduces the efficiency with which clinical knowledge is gleaned, negatively impacting patients. Currently, the conduct of clinical trials indicates a loss of balance between the processes used in running a trial and the purpose for which it is conducted. There is a need to agree on the nature of evidence and the standards of evidence truly required. Currently, the nature of performance metrics often focuses on delivering different parts of the trial process and is not well aligned with the overall objectives of medicines development.
Is it possible to simplify (some of) the superstructure without harming trial patients or jeopardizing the credibility of results? These superstructures can impose a negative toll on clinical trial efficiency and development of clinical knowledge. Hindering the development of good quality knowledge does not benefit patients. We believe that there is a need to reconsider what makes a clinical trial robust, relevant, and from that starting point, adopt a risk proportionate approach to trial design and management. If one considers the attributes of a robust and relevant clinical trial and applies a riskbased approach to trial management, a more efficient model with a simplified superstructure emerges. For example, there is a perception that intensive (and expensive) source data verification is essential for reliable results. However, central statistical monitoring of trialrelated data, in combination with targeted site monitoring informed by statistical analysis, can be a more effective and efficient method of detecting important errors during the conduct of a trial and identifying opportunities for improvement prospectively. 22 Initiatives for reducing complexity CTTI and ICH are working to make clinical trials more efficient and responsible for clarifying the processes used and the roles and responsibilities of the parties conducting the trials. While these initiatives hold tremendous potential for promoting efficiency in these key areas, poor alignment of incentives for all actors in the clinical trial ecosystem remains a significant obstacle. To overcome the resistance posed by poor alignment, novel business models will be required for service providers currently incentivized by the increasing complexity of the superstructure. New business models should be driven by quality delivered and efficiency gains, not volumes of procedures (e.g. monitoring).
ICH has initiated a good clinical practice renovation, commencing with a revision of ICH E8 General Considerations for Clinical Trials. 23 This ICH initiative represents an important opportunity to re-center the focus of clinical trial conduct on generating the evidence needed to support decision making and identifying those standards truly required to support delivery of new and better medicines and better uses of existing medicines. The initiative has an ambitious agenda covering revision of both ICH E8 and ICH E6. 23 It is essential that this opportunity is seized by all parties involved.
Leveraging clinical trial transparency

Analysis of patient-level data from multiple trials
Within the past decade, lively debate about the public availability of data from completed clinical trials has led to a broad consensus that such data should rightfully be shared. A primary argument in favor of this consensus is that sponsors and trialists have an obligation to trial participants to share results. With this shift, and the resultant increase in clinical trial transparency, comes the unprecedented opportunity for improving the future usefulness of clinical trial outcomes and the efficiency of their conduct. In coming years, it is highly likely that patient-level data from all completed clinical trial results will be made available to researchers, a practice that will dramatically change the way in which clinical trials are conducted.
Until now, virtually all clinical trials have been designed as stand-alone endeavors meant to answer one (or perhaps a few) clearly defined research questions with very little reuse of previously obtained data. Currently, researchers and sponsors occasionally reuse and combine clinical trial results (e.g. by way of metaanalysis based on published summary data) to obtain a better estimate of a given treatment's effect size or safety profile, a practice which represents an incremental step from stand-alone analysis. Efficient secondary use of data that goes beyond just combining data from a single development program to address other research questions is only now becoming possible and likely to emerge as a powerful tool in the future.
Future participant-level data sharing will enable a much wider application and reuse of clinical trial data, including, but not limited to, novel biologic or clinical findings, indirect comparisons of treatment options, 24 borrowing of data, 10 establishment of virtual control groups, 25 algorithms for individualized decision making, or treatment responsiveness of subgroups. 26 Indeed, the recently completed New England Journal of Medicine Systolic Blood Pressure Intervention Trial (SPRINT) data analysis challenge 26 has demonstrated the power of patient-level data sharing to produce new findings-even from a single dataset from one large trial. The ability to reveal new knowledge through this type of analysis will likely be amplified when data from multiple clinical trials are combined.
While the prospects of clinical trial data sharing are easy to envisage, many bottlenecks remain to be resolved: (1) alignment of incentives for all actors, including trial participants, trialists (investigators and sponsors), and those who wish to make secondary use of their data; (2) establishment of procedures to ensure robust protection of patient identity and privacy; (3) governance and data sharing agreements; (4) more efficient ways to obtain ethics committee approval; and (5) technical interoperability and accessibility of datasets, the latter should also minimize the opportunity cost to researchers of making data available. Additional bottlenecks may surface as more secondary analyses are carried out. 26 The concept of data sharing on a large scale is a very recent development, and its full value has not yet been realized. As the power of secondary analysis of patientlevel data continues to develop, all actors in the clinical trial community are faced with the challenge of addressing issues of common interest. Furthermore, all clinical trial actors must consider the importance of preplanning for secondary data use during initial clinical trial design. The sooner issues slowing data sharing and secondary analysis are resolved, the sooner the clinical trial community can make the quantum leap from standalone to best-utilized clinical trials.
Clinical trials in public view
Transparency in clinical trials also benefits patients and the public. Availability of information on clinical trials and their results builds trust (no trial can be ''hidden''). This level of trust is critically important, given that all clinical research relies on the willingness of individual patients and volunteers to consent and participate in trials. The knowledge that the data collected will always be analyzed and publically reported is an important pillar of that trust, as is a general understanding of the regulatory processes that surround the conduct of clinical trials and use of their results in regulatory decision making. Furthermore, when information about trials is publicly available, individuals are empowered to learn about trials for which they may be eligible. Finally, when trial results that provide a foundation for patients' own medical care are available, individuals can be better informed to support their own health-care choices.
In coming years, true innovation will arise from the utilization of shared patient-level data to drive the development of medicines and optimization of their use. Patient data (from clinical trials and real-world experience) with robust protection of the individuals' personal identity and privacy must be seen as a common good, analogous to the human genome project. Innovation comes from applying that data to drive the development of medicines and their use. Given the value of these data, from both an analytical and public access perspective, hiding or sequestering data as multiple, restricted, commercial commodities will be both counterproductive and ethically unsound.
Conclusion
In order to yield meaningful data, the randomized controlled trial must adapt and evolve to respond to a changing environment so that the quality of trial design and the efficiency with which clinical knowledge is generated can be improved. Collaborative efforts have driven change in the right direction, and appreciable progress has already been facilitated by dedicated organizations, especially CTTI, which have focused on some of the challenges described above. However, CTTI and others have their work cut out for them in the near future as complex issues stemming from globalization, external validation, study populations, precision medicine, and clinical trial transparency, among others, continue to shape the clinical trial landscape.
